-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- CUSTOMER EXPERIENCE MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DOCUMENT MANAGEMENT
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards
Tullio Cappelletto, Director, Marketing & Sales“It all started with our FlexAssure™ Flexible Instruments, combining two proprietary technologies, our BeamPath™ waveguide and iCage™ sheath, to meet our mission to deliver a better surgical experience and reduce complications every day,” noted Tullio Cappelletto, OmniGuide’s Director of Marketing and Sales.
BeamPath technologies leverage OmniGuide’s exclusive multi-layered, polymeric fiber technology for maximum flexibility and the photonic band gap effect for high-fidelity laser light transmission so surgeons can count on predictable laser-tissue effects, regardless of their instruments’ orientation. Cladding each fiber is their exclusive iCage™ technology, a proprietary stainless-steel sheathing that protects fiber cores with every turn or twist of the instrument while ensuring laser light remains within the fiber even if it breaks.
“Surgeons immediately realized the value of our CO2 fiber products... the fibers were designed to be more flexible or not leave glass (silica) in the surgical field, and if they failed, iCage kept the light in the fiber... that means safety for patient and user, which is a key to delivering a better surgical experience,” said Cappelletto.
Moreover, “Our fibers offered surgeons more control to excise tissue confidently, knowing that our laser helped them maintain the margins they wanted, potentially eliminating collateral thermal damage and helping optimize viable native tissue.”
Today OmniGuideRobotics™ serves as a core business unit responding to the rapidly evolving field of robotic-assisted surgeries, offering essential products to help surgeons and hospitals access minimally invasive options for major surgery.
From the flexible instrumentation, such as the FlexGuide™ Robotic Conduit, to dedicated FlexAssure Fibers products, such as the Velocity™, Elevate™, and BP-Robotic™ fibers, each product matches surgeons’ performance expectations for tasks and intensity.
OmniGuide products are used across specialties, from transoral robotic-assisted surgery (TORS) in Otolaryngology to robot-assisted myomectomies, hysterectomies, and laparoscopies for endometriosis in Gynecology to tissue-sparing partial nephrectomies in Urology, OmniGuideRobotics™ products serve as critical adjacents and accelerators for robotic surgery.
“We expect the development in robotics to accelerate and intend to be at the leading edge with our new technologies and techniques,” said Cappelletto.
OmniGuide’s recent investment in the OmniGuide Global Training Center in Billerica, MA, headquarters along with the Innovation Institute in Katlenburg-Lindau, Germany, demonstrates a commitment to future innovation beyond serial product line extensions. Commissioned in late- 2022, the OmniGuide Global Training Center provides a comprehensive technical and clinical instruction curriculum, aiding healthcare providers and support teams in gaining valuable insights from subject matter experts. OmniGuide’s Innovation Institute leads efforts to develop advanced biomedical software and sensors for future image-guided and AI capabilities.
“We’re very excited about the future of bringing the potential of biosensors and AI to our platforms and, by extension, how these advancements will impact robotic-assisted surgeries,” said Cappelletto.
It all started with our FlexAssure™ Flexible Instruments, combining two proprietary technologies, our BeamPath™ waveguide and iCage™ sheath, to meet our mission to deliver a better surgical experience and reduce complications every day
Moving forward, OmniGuide aims to leverage the unmatched competencies of its laser, fiber, and software solutions to revolutionize robot-assisted surgeries and help patients receive the best treatment options.
OmniGuide™ Holdings and UROTECH (Medi-Globe Group Subsidiary) Announce Partnership to Expand Global Urology Patient Therapies
Friday, February 23, 2024
BOSTON- OmniGuide™ Holdings (OGH) and UROTECH® (part of the Medi-Globe Group, a subsidiary of DCC plc) have announced a new partnership to strengthen UROTECH's technology portfolio for urologists. As part of the collaboration, the partnership will work with urologists to build a global network for RevoLix™ HTL (Hybrid Thulium Laser Therapy) specifically for kidney stones and benign prostatic hyperplasia (BPH).
UROTECH is one of the leading medical technology manufacturers in the field of minimally invasive urology. The treatment of kidney stones is at the heart of UROTECH's work, which is committed to the highest quality standards for its products and clinical experience. As a determined and reliable medical partner, UROTECH supports the daily work of urologists.
Surgeons and nurses recognize OmniGuide's ability to deliver advanced solutions for some of the most important surgical therapies in urology. OmniGuide's innovative focus on robotics, precision light therapies and biosensing software enables the company to cover a wide range of urological procedures and reduce complications every day.
The aim of the global collaboration is to support future surgical trends by providing access to data and insights for urological decisions. The partnership will accelerate these efforts as two global companies work toward a common goal and bring their surgical expertise.
OmniGuide Urology will support projects with UROTECH including:
• Scaling global capacity for Kidney Stones and BPH Treatments through the newly launched RevoLix™ HTL Hybrid Thulium Laser.
• User-centered strategies for existing urologists, delivering solutions to better support a great clinical experience.
• Increase advocacy through partnering and establishing a forum in urology.
• Developing a biosensing software platform in partnership with the OmniGuide™ Institute for Biomedical Innovation.
“UROTECH is known for its customer focus and the user-centric development and distribution of innovative solutions for urologists worldwide. The partnership with OmniGuide fits into this mindset, to make the revolutionary all-in-one RevoLix HTL laser technology and its great benefits available to our customers,” said Dr. Markus Schönberger, Director Business Development and Head of the Strategic Business Unit Urology of the Medi-Globe Group.
“Biosensing Innovation is increasing both the need to collaborate and share data,” said M.T. Henderson CEO OmniGuide Holdings™ (OGH). “Solutions that connect outcomes with recent technology are at the core of our collective purpose. We are proud to partner with UROTECH to expand our shared vision of helping to improve patient lives, fueled by innovation-forward therapies.”
Company
OmniGuide
Management
Tullio Cappelletto, Director, Marketing & Sales
Description
OmniGuide combines its proprietary flexible polymer-based CO2 fiber with robotics to provide patient safety and precision during surgeries.
